Previous 10 | Next 10 |
home / stock / nvsef / nvsef news
Quick Take Checkmate Pharmaceuticals ( CMPI ) intends to raise $75 million from the sale of its common stock stock in an IPO, according to an amended registration statement . The company is advancing a biologic particle treatment for melanomas and head & neck squamous cell carcinomas....
Gilead ( GILD ) - first, the bear case GILD reported Q2 results Thursday. The stock, which had begun underperforming the sector ( IBB ), dropped further, and on a weak day for biotech Friday closed down 3.9% at $69.53. After having led the sector up this year, it is now lagging IBB's to...
Quick Take Checkmate Pharmaceuticals ( CMPI ) has filed to raise $75 million in an IPO of its common stock, according to an S-1 registration statement . The company is a clinical stage biopharma advancing a drug treatment candidate for melanoma and head & neck cancer. CMPI has produ...
By Guney Kaya Novartis ( NVS ) has been a key pick for us during the coronavirus pandemic. Although a quintessential biopharma company, it has one of the safest pipelines with dozens of therapies already in registration phase or phase III. Their strategic shift to being a more value-add an...
Novartis AG (NVS) Q2 2020 Earnings Conference Call July 21, 2020, 8:00 am ET Company Participants Samir Shah - Global Head, IR Vas Narasimhan - CEO Harry Kirsch - CFO Marie-France Tschudin - President, Novartis Pharmaceuticals Susanne Schaffert - President, Novartis Oncology ...
Quick Take iTeos Therapeutics ( ITOS ) intends to raise $151 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a range of treatments for various cancers, including solid tumors. ITOS is pursuing treatments for...
The following slide deck was published by Novartis AG in conjunction with their 2020 Q2 earnings Read more ...
Quick Take Annexon ( ANNX ) intends to raise $150 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatments for autoimmune and neurodegenerative conditions. ANNX is pursuing multiple treatment programs with...
Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
Quick Take ALX Oncology ( ALXO ) intends to raise $128 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing treatment candidates for various blood and solid tumor cancer conditions. ALXO is pursuing treatments in...
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...